CN116178494A - 一种解酒多肽 - Google Patents
一种解酒多肽 Download PDFInfo
- Publication number
- CN116178494A CN116178494A CN202310330267.6A CN202310330267A CN116178494A CN 116178494 A CN116178494 A CN 116178494A CN 202310330267 A CN202310330267 A CN 202310330267A CN 116178494 A CN116178494 A CN 116178494A
- Authority
- CN
- China
- Prior art keywords
- liver
- alcohol
- hangover
- adh
- hangover composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 9
- 229920001184 polypeptide Polymers 0.000 title claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 4
- 230000002075 anti-alcohol Effects 0.000 title abstract description 11
- 230000000694 effects Effects 0.000 claims abstract description 28
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 235000013305 food Nutrition 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- 210000004185 liver Anatomy 0.000 claims description 34
- 206010019133 Hangover Diseases 0.000 claims description 10
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 claims description 8
- 229940118019 malondialdehyde Drugs 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 claims description 6
- 108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 claims description 6
- 230000004060 metabolic process Effects 0.000 claims description 6
- 206010067125 Liver injury Diseases 0.000 claims description 5
- 231100000753 hepatic injury Toxicity 0.000 claims description 5
- 230000001476 alcoholic effect Effects 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 claims 1
- 108010082126 Alanine transaminase Proteins 0.000 claims 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 claims 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 230000035987 intoxication Effects 0.000 claims 1
- 231100000566 intoxication Toxicity 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 238000004904 shortening Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- 210000002966 serum Anatomy 0.000 description 21
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 16
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 16
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 230000002496 gastric effect Effects 0.000 description 12
- 102000016938 Catalase Human genes 0.000 description 9
- 108010053835 Catalase Proteins 0.000 description 9
- 229960003180 glutathione Drugs 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 102100024889 Cytochrome P450 2E1 Human genes 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000007848 Alcoholism Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- JMZOMFYRADAWOG-UHFFFAOYSA-N methyl 7-methoxy-4-(7-methoxy-5-methoxycarbonyl-1,3-benzodioxol-4-yl)-1,3-benzodioxole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1C(=O)OC JMZOMFYRADAWOG-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000004149 ethanol metabolism Effects 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000010813 internal standard method Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000849 liver cell damage Toxicity 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明属于生物医药技术领域，具体提供了一种全新的活性解酒肽,该肽的序列如SEQ ID NO.1所示；本发明还对应提供了含该肽的组合物，可以是药品、保健品或食品。本发明的肽分子量小、易于合成、安全无毒副作用，安全性和实用性良好。
Description
技术领域
本发明属于生物医药技术领域，具体涉及一种全新的活性解酒肽。
背景技术
酒文化不仅是中国文化的重要组成部分，在国外社交、外交甚至军队等场合亦流行，但醉酒导致的问题很多。醉酒是酒精中毒的俗称，是指患者一次饮大量酒精（乙醇）后发生的机体机能异常状态，分为急、慢性醉酒。
众所周知，酒的主要成分乙醇主要是通过口腔、食管、胃、肠粘膜等吸收至组织器官，然后主要经过肝脏代谢。乙醇在肝脏内主要通过三个酶体系进行代谢：乙醇脱氢酶（ADH）体系、细胞色素酶（P4502E1）体系和过氧化物酶（CAT）体系，在适量或少量饮酒时，则主要通过ADH体系进行代谢。
基于酒精代谢和酒精性肝损伤的形成机制，大量研究证明，酒精及其有害代谢产物在体内积累是造成酒精性肝损伤的主要根源。因此，解酒，加快酒精代谢、减少有害代谢产物在体内停留对于维持人体健康具有重要的意义。目前，较多人已宣称得到解酒方法，但仍需基于生物技术进行创新。
发明内容
本发明的一种目的在于提供一种全新的活性解酒肽，氨基酸序列为Phe-Ala-Pro-Glu-Gly；
本发明的另一个目的在于进而提供该五肽用于解酒的应用；
相应地，本发明还提供了含该五肽的组合物，如为解酒类产品，可以是用于解酒的药物、保健品或食品。
进一步地，任一所述解酒，包括防治急慢性酒精中毒和/或酒精性肝损伤，可至少产生如下任一效果：
（1）能够加快体内酒精代谢；
（2）能够缩短乙醇及有害代谢产物在体内的停留时间；
（3）提高肝脏中ADH、ALDH和/或CYP2E1酶的活性；
（4）提高血液中ADH、T-AOC、GSH和/或CAT的水平；
（5）提高肝脏中T-AOC、GSH和/或CAT的水平；
（6）降低血液中AST和/或ALT酶的含量；
（7）降低肝脏中TG的水平；
优选地，所述的组合物为解酒类药物，可以是颗粒、胶囊、口服液等。
进一步地，所述的解酒类药物还包含本领域技术人员公知的药用辅料。
本发明的五肽分子量小、易于合成、安全无毒副作用，安全性和实用性良好。与现有技术中已有的解酒剂等药物相比，原料简单易于制备，单独灌用五肽能达到很好的解酒效果，更加便于在药物、食品及保健品中的应用，更加易于其在解酒中广泛应用。
附图说明
图1为本发明五肽对ADH激活率的结果示意图；
图2为本发明所述五肽对小鼠体内酒精浓度的结果图；
图3为本发明所述五肽对小鼠血清和肝脏中乙醇代谢酶的结果图（A：血清中ADH活性，B：肝脏中ADH活性，C：肝脏中ALDH活性，D：肝脏中CYP2E1活性）；
图4为本发明所述五肽对小鼠血清中抗氧化酶的结果图（A：小鼠血清中T-AOC的含量，B：小鼠血清中GSH的含量，C：小鼠血清中CAT的含量，D：小鼠血清中MDA的含量）；
图5为本发明所述五肽对小鼠肝脏中抗氧化酶的结果图（A：肝脏中T-AOC的含量，B：肝脏中GSH的含量，C：肝脏中CAT的含量，D：肝脏中MDA的含量）
图6为本发明所述五肽对小鼠肝损伤标记酶的影响（A：小鼠血清中AST活性，B：小鼠血清中ALT活性）；
图7为本发明所述五肽对脂质代谢的影响（肝脏中TG的含量）。
实施方式
利用固相法化学合成本发明的五肽Phe-Ala-Pro-Glu-Gly，下面通过具体实施方式对本发明的技术方案进行更加清楚、完整的描述，以便于本领域技术人员对本发明的理解，但是并不用于对本发明保护范围的限制。
实施例
体外测定五肽（FAPEG）对ADH活性的影响，测定方法如下：准备4支测定管，在测定管中加入150μL缓冲液（包括75μL 0.1mM PH 8.8的焦磷酸钠缓冲液，25 μL 11.5% (v/v)的乙醇，50μL 27mM NAD+），再加入50μL不同浓度（分别为2mmol/L、4mmol/L、6mmol/L、8mmol/L）的FAPEG溶液，然后在37℃孵育5min；温育后在各支测定管中立即加入50μL、0.2U/mL的ADH酶溶液并充分混匀，然后读取各溶液在340nm波长的吸光度变化，每间隔1min读取一次，连续测定5min。以加入蒸馏水的吸收值为空白组。计算相对酶活力，结果如图1所示。
图1结果表明，五肽FAPEG可以显著提高体外ADH的激活率。
实施例
本实施例通过动物实验进一步证明本发明所述的五肽对小鼠酒精代谢的影响，具体实验如下：
取64只昆明小鼠（20-22g），在动物房适应性喂养7天，然后随机分为4组：空白对照组（Control）、模型组（Model）、阳性对照组（Positive）、五肽组（FAPEG）。
空白组：每天按照小鼠体重灌胃生理盐水（30mg/Kg），灌胃生理盐水后一次性灌胃生理盐水12ml/Kg；
模型组：每天按照小鼠体重灌胃生理盐水（30mg/Kg），灌胃生理盐水后一次性灌胃56度白酒12ml/Kg；
阳性组：每天按照小鼠体重灌胃联苯双酯乳浊液（150mg/Kg），灌胃联苯双酯乳独液后一次性灌胃56度白酒12ml/Kg；
五肽组：每天按照小鼠体重灌胃五肽溶液（30mg/Kg），灌胃五肽后一次性灌胃56度白酒12ml/Kg。
上述实验组在第一天灌胃白酒（空白组灌胃生理盐水）2h后，进行眼球取血于枸橼酸钠抗凝剂中，混匀，4℃备用。利用气相色谱内标法检测血液中乙醇浓度，结果如图2所示；酒精摄入导致模型组小鼠体内的乙醇浓度在2小时内急剧上升至4.85mg/ml。而与模型组相比，30mg/Kg的五肽灌胃处理（五肽组）可使乙醇含量显著降低至3.01mg/mL，清除率达到38%以上，直接降低了酒精对小鼠的毒性作用。
然后继续进行灌胃处理，按照上述的灌胃方法、连续灌胃7天，最后一次灌胃后2h，收集小鼠的血清和肝脏组织：取小鼠的血液样品在转速为4000rpm、温度为4℃的条件下离心10min，制备血清；肝脏用生理盐水制备成10%的肝匀浆，然后浆肝匀浆样品在转速为3500rpm、温度为4℃条件下离心10min，然后收集肝匀浆的上清液。对灌胃7天收集的血清及肝脏进行以下检测：
采用试剂盒（本领域技术人员公知方法）检测血清中的ADH酶活性，检测肝脏中ADH、ALDH以及CYP2E1的活性，结果如图3所示；小鼠在连续摄入乙醇7天后，模型组肝脏中ADH和ALDH活性显著降低，CYP2E1活性升高。
检测结果证明，连续灌胃本发明所述的五肽7天，可以显著提高血清中ADH（p＜0.05）活性，显著提高肝脏ADH（p＜0.05）和ALDH（p＜0.01）酶活性、降低CYP2E1（p＜0.01）的水平，从而提高了小鼠的酒精代谢能力。五肽（FAPEG）通过增强乙醇代谢酶活性从而加快乙醇代谢，减少乙醇代谢物及ROS对肝脏造成的损伤。
基于上述收集的小鼠血清和肝匀浆上清液，采用试剂盒测定小鼠血清和肝组织的抗氧化能力（T-AOC）、谷胱甘肽（GSH）、过氧化氢酶（CAT）以及丙二醛（MDA）的水平，结果图4和图5所示；图4结果连续灌胃7天五肽可显著增强小鼠血清中T-AOC（p＜0.01）、GSH（p＜0.01）、CAT（p＜0.05）抗氧化酶的水平，显著降低了血清中MDA（p＜0.01）水平。图5结果表明连续灌胃7天五肽显著增强了小鼠肝脏中T-AOC（p＜0.001）、GSH（p＜0.001）、CAT（p＜0.05）抗氧化酶的水平，降低肝脏中MDA（p＜0.05）的含量，减少了持续大量饮酒对小鼠造成的氧化应激损伤。
基于上述收集的小鼠血清，采用试剂盒（本领域技术人员公知的方法）测定小鼠血清中的AST以及ALT的活性，结果如图6所示。由图6结果可知，与模型组相比，连续灌胃7天五肽显著降低了血清中AST（p＜0.01）及ALT（p＜0.05）的水平。因此，五肽对酒精诱导造成的肝细胞损伤具有保护作用。
基于上述收集的肝匀浆上清液，采用试剂盒（本领域技术人员公知的方法）测定小鼠肝脏中TG的含量，结果如图7所示。由图7结果可知，与模型组相比，连续灌胃7天本发明所述的五肽能够降低肝脏中TG（p＜0.05）的含量，所以，对于肝脏脂质代谢具有很好的保护作用。
Claims (6)
1.SEQ ID NO.1所示多肽在制备解酒组合物中的应用。
2.如权利要求1所述的应用，其特征是，该解酒组合物用于防治急慢性醉酒和/或酒精性肝损伤。
3.如权利要求1所述的应用，其特征是，所述解酒组合物用于产生如下至少一种效果：
1）加快体内酒精代谢；
2）缩短酒精有害代谢产物在体内的停留时间；
3）降低血液中丙二醛、谷丙转氨酶和/或谷草转氨酶的含量；
4）降低肝脏中丙二醛、ROS氧自由基、总胆固醇和/或CYP2E1酶的水平；
5）提高血液中ADH、T-AOC、GSH和/或CAT的水平；
6）提高肝脏中T-AOC、GSH和/或CAT的水平；
7）提高肝脏中ADH和/或ALDH酶的活性。
4.如权利要求1所述的应用，其特征是，所述解酒组合物是用于解酒的药品、保健品或食品。
5.含SEQ ID NO.1所示多肽的解酒组合物。
6.如权利要求5所述的解酒组合物，其特征是，所述解酒组合物是药品、保健品或食品。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310330267.6A CN116178494A (zh) | 2023-03-30 | 2023-03-30 | 一种解酒多肽 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310330267.6A CN116178494A (zh) | 2023-03-30 | 2023-03-30 | 一种解酒多肽 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116178494A true CN116178494A (zh) | 2023-05-30 |
Family
ID=86442548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310330267.6A Pending CN116178494A (zh) | 2023-03-30 | 2023-03-30 | 一种解酒多肽 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116178494A (zh) |
-
2023
- 2023-03-30 CN CN202310330267.6A patent/CN116178494A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lieber | The metabolism of alcohol | |
| CN111560331B (zh) | 一株副干酪乳杆菌及其应用 | |
| KR102460589B1 (ko) | 글루타치온과 알데히드탈수소효소를 함유하는 숙취해소제 | |
| KR20160008425A (ko) | 세리포리아 락세라타 배양액 추출물 유래의 세포외다당체를 유효성분으로 함유하는 간기능 개선용 조성물 | |
| CN114214366A (zh) | 一种预防和治疗贫血的小肽粉和血红素之肽红复方药物及其制备方法和应用 | |
| CN117568231A (zh) | 一株约氏乳杆菌bw002及其在防治和/或修复肝损伤中的应用 | |
| JP2023514528A (ja) | グルタチオンとアルデヒド脱水素酵素を含有する二日酔い解消剤 | |
| CN104415023A (zh) | 预防或/和治疗胰岛素抵抗及相关病症的组合物 | |
| CN116178494A (zh) | 一种解酒多肽 | |
| WO2016010183A1 (ko) | 세리포리아 락세라타 배양액 추출물 유래의 세포외다당체를 유효성분으로 함유하는 지질 관련 대사 개선용 조성물 | |
| CN114917208A (zh) | 一种白酒在制备改善肠屏障功能及肠道菌群药物中的应用 | |
| JP2009274961A (ja) | 吸収促進剤 | |
| US10004679B2 (en) | Compositions of Amorphophallus konjac and methods for their use in skin care | |
| CN116693604A (zh) | 解酒肽 | |
| KR101655882B1 (ko) | 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 숙취해소용 조성물 | |
| CN114081893A (zh) | 花色苷和果胶联用在制备预防和/或治疗非酒精性脂肪肝药物中的应用 | |
| JPH07285881A (ja) | アルコール代謝促進剤 | |
| CN115039878A (zh) | 一种调节脂肪代谢功能的组合物 | |
| CN110664984A (zh) | 一种具有解酒护肝功效的组合物及其制备方法 | |
| Ciftci et al. | Effects of some drugs on enzymatic activity of glucose 6-phosphate dehydrogenase from chicken erythrocytes in vitro | |
| CN114272260B (zh) | 一种海洋天然产物解酒保肝口服液、制备方法以及应用 | |
| CN111686236B (zh) | 一种解酒保肝护脑胶囊 | |
| US20230144882A1 (en) | Use of adenosine deaminase and adenosinedeaminase modifier in preparation of medicamentfor wound repair in patient with diabetes | |
| CN116676240B (zh) | 鼠李糖乳酪杆菌及其在预防或治疗酒精性肝病中的应用 | |
| KR102214565B1 (ko) | 프로텍틴 dx을 포함하는 숙취해소용 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |